Organ transplant recipients (OTRs) have an increased risk of developing keratinocyte carcinomas (KCs). The aim of this study was to correlate infection with human papillomaviruses (HPVs) belonging to the beta genus (Betapapillomavirus (Beta-PV)) at transplantation with later development of KCs. In a cohort study, sera collected between 1 year before and 1 year after transplantation of OTRs transplanted between 1990 and 2006 were tested for antibody responses against the L1 capsid antigen of Beta-PV and other HPV genera (Gamma-, Mu-, Nu-, and Alpha-PV) using multiplex serology. The OTRs were followed for a maximum of 22 years. Cox regression models with KC, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC) as outcome variables were used. Out of 445 OTRs, 60 had developed KC: 14 developed only SCC, 24 only BCC, and 22 both types of KC. The timedependent hazard ratio (HR) to develop either or both types of KC, adjusted for age, sex, and transplanted organ, in tested Beta-PV-seropositive OTR around the time of transplantation compared with Beta-PV-seronegative OTR was 2.9 (95% confidence interval (CI) 1.3-6.4). The HR for SCC was 2.9 (95% CI 0.99-8.5) and for BCC it was 3.1 (95% CI 1.2-8.0). There was also an association between Mu-PV seropositivity and KC, but there were no significant associations between other HPV genera tested and KC. A positive seroresponse for Beta-PV around transplantation significantly predicted the development of KC in OTRs up to 22 years later, providing additional evidence that infection with Beta-PV has a role in KC carcinogenesis.
INTRODUCTION
Keratinocyte carcinomas (KCs) are the most prevalent malignancies seen in organ transplant recipients (OTRs). The incidence of squamous cell carcinoma (SCC) is 60-250 times increased compared with the general population, and for basal cell carcinomas (BCCs) this is 10-40 times (Hartevelt et al., 1990; Euvrard et al., 2003; Moloney et al., 2006; Tessari et al., 2010) . In OTRs, SCCs are more frequently observed than BCC, with a SCC/BCC ratio of 5:1 compared with the general population where a SCC/BCC ratio of 1:4 is found (Wisgerhof et al., 2009) .
Life-long immunosuppressive therapy is the most important risk factor for developing KCs in OTRs. Other important risk factors include sun exposure, male gender, older age, smoking, and fair skin with susceptibility to sunburn. These are similar risk factors as in the immunocompetent population (Terhorst et al., 2009) . A role of human papillomaviruses (HPVs) in the development of KC has also been frequently suggested (Proby et al., 2011; Andersson et al., 2012; Neale et al., 2013) .
HPVs are small double-stranded DNA viruses that infect epithelia of the skin or mucosa. Over 150 different types have been described (de Villiers et al., 2004; Bernard et al., 2010) . HPV has been estimated to have a causative role in 5.2% of all human cancers (Parkin, 2006) . HPV types are classified in different classes (1-4) by the IARC (International Agency for Research on Cancer) based on their carcinogenic potential (IARC, 2007; Bouvard et al., 2009 ).
The first time that HPV infection was linked with KC was in patients with a rare autosomal recessive disease called epidermodysplasia verruciformis (Jablonska et al., 1972) . Patients with epidermodysplasia verruciformis have an increased susceptibility to widespread Beta-papillomavirus (Beta-PV) infections of the skin that progress to SCC in onethird of the patients, mainly on sun-exposed sites (Lutzner, 1978) . In the years after transplantation, OTRs start to develop a clinical picture that resembles that of patients with epidermodysplasia verruciformis. Epidemiological and experimental data have advocated a potential carcinogenic role of cutaneous HPV infection in skin cancer, especially of SCC in the immunosuppressed population (Bouwes Bavinck et al., 2008) .
There are different methods to detect Beta-PV infection, based on measurement of viral protein, viral DNA, or serum antibody responses (Aldabagh et al., 2013) . Serological responses are considered as the most consistent marker of biologically relevant Beta-PV infection (Andersson et al., 2012) , reflecting a past or present infection strong enough to evoke an immune response.
Most studies investigating the association between serological responses to HPV and SCC are cross-sectional or casecontrol studies that were carried out in the immunocompetent population, and showed an association between detection of Beta-PV antibodies and SCC (Feltkamp et al., 2003; Karagas et al., 2006; Waterboer et al., 2008; Karagas et al., 2010; Bzhalava et al., 2013) . As far as we know, cohort studies investigating the association between serological responses to HPV and later development of a first KC were not carried out in OTR (Aldabagh et al., 2013) . Therefore, we designed a retrospective follow-up study to establish whether there is a relationship between the presence of serological responses to HPV, in particular Beta-PV, around transplantation and the development of KC (SCC and BCC) in the years after the organ transplantation.
RESULTS
The baseline characteristics of the 445 OTRs included in the study are shown in Table 1 . The majority of patients were male (65%) and most patients (79%) underwent kidney transplantation. The mean age of the patients at transplantation was 47.3 years and the mean follow-up after transplantation was 11.8 year. A mean of 4.2 sera (range 1-17) was available from 1 year before to 1 year after transplantation. Among the patients who developed KC, the mean time from transplantation until the first KC was 7.7 years. Supplementary Table S1 online shows the percentages of OTRs who were seropositive for any HPV type tested between 1 year before and 1 year after the transplantation, for all OTRs together and stratified for those with KC, SCC, and BCC. Table 2 summarizes Supplementary Table S1 online and provides the percentages of OTRs who were seropositive for at least one HPV type per HPV genus (Beta-, Gamma-, Mu-, Nu, or Alpha-PV). Seroresponses against the beta genus were more frequently observed in the patients with KC compared with patients without KC, reaching statistical significance (P ¼ 0.005; Table 2 ). Patients who were seropositive for at least one HPV type of a specific genus had a greater probability for being seropositive for another HPV genus ( Supplementary Table S2 online) .
The cumulative incidence of KC in Beta-PV-seronegative and Beta-PV-seropositive OTR is depicted in Figure 1 and Supplementary Figure S1 online. Log-rank tests were performed and showed a significant difference between Beta-PV-seropositive and -seronegative OTRs (P ¼ 0.043). The Kaplan-Meier plots for SCC and BCC showed similar curves as the plots for KC ( Supplementary Figures S2 and S3 online). Table 3 shows the time-dependent nonadjusted hazard ratios (HRs) and the HRs adjusted for age at transplantation, sex, and type of transplantation for the development of KC, SCC, and BCC. A positive association was found between seropositivity for at least one Beta-PV type detected between 1 year before and 1 year after the organ transplantation and the development of KC, SCC, and/or BCC. After adjustment, Mu-PV seropositivity was also associated with KC ( Table 3 ). The Cox proportional hazard analyses (Table 3 ) and the Kaplan-Meier plots of cumulative incidence of KC, SCC, and/or BCC in HPV-seronegative and -seropositive OTRs for the other HPV genera tested (Gamma-, Nu-, and Alpha-PV) showed no significant association between seropositivity against any of these HPV genera ( Supplementary Figures S1-3 
online).
Beta-PV species 1 (specifically HPV8 and HPV20) and Beta-PV species 3 (specifically HPV75 and HPV76) were most relevant for the positive association between Beta-PV seropositivity and the development of KC ( Supplementary Figure S4 online). The potential importance of these Beta-PV types was confirmed for HPV8 and HPV75 by conditional step forward regression analyses, and a statistically significant negative association was observed for HPV96 (Table 4 ).
Beta-PV species 1 (HPV8 and HPV20) and Beta-PV species 3 (HPV76) were also associated with the development of SCC (Supplementary Figure S5 online), confirmed by conditional step forward regression analyses (Table 4) . A statistically significant negative association was found for HPV24 and HPV38 (Table 4 ).
Beta-PV species 2 (HPV15) and species 3 (HPV75 and HPV76) were relevant for the development of BCC (Supplementary Figure S6 online), which was confirmed in the conditional step forward regression analyses for HPV15 and HPV26, whereas there was a statistically significant negative association with HPV9 (Table 4 ).
DISCUSSION
We have found a statistically significant association between the development of KC, SCC, and BCC after transplantation and antibody responses to one or more Beta-PV types, measured in serum drawn in a window between 1 year before and 1 year after organ transplantation. The antibody response against Beta-PV types was specific for the beta genus, as there were no significant associations for positive seroresponses against the gamma, nu, and alpha genera with the development of KC, SCC, or BCC. Interestingly, we also found a positive association between KC and Mu-PV seropositivity, an HPV genus not recognized previously as potentially associated with KC development.
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Beta-PV Associated with Skin Cancer in OTR So far, most studies investigating HPV seroresponses in association with KC development concerned cross-sectional and case-control studies in the immunocompetent population (Aldabagh et al., 2013) . We are aware of only a few published cohort studies that were performed in the immunocompetent population. A Scandinavian study described a weak association for overall Beta-PV seropositivity before SCC diagnoses, whereas a significant association was observed for Beta-PV species 2 (odds ratio (OR) ¼ 1.3, 95% confidence interval (CI) 1.1-1.7), and for serum samples taken 418 years before diagnosis (OR ¼ 1.8, 95% CI 1.1-2.8) (Andersson et al., 2012) . A population-based cohort study in Australia revealed no associations between the presence of any of the Beta-PV antibodies and the occurrence of SCC (Plasmeijer et al., 2011) . However, among people who were o50 years old in 1992, the presence of Beta-PV antibodies was associated with a 2-fold increased risk of SCC (Plasmeijer et al., 2011) . In the United Kingdom, a prospective pilot study found no significant differences in seropositivity of any of the 38 HPV types (Casabonne et al., 2007) . One study investigated the possible role of seropositivity for different HPVs in the incidence of a subsequent KC in 107 patients with a follow-up of 5 years who were enrolled in a previous case-control study. HPV seropositivity at baseline was strongly associated with the risk of developing a second SCC after 5 years for a number of beta and gamma HPV types, but no association was found for developing a second BCC (Paradisi et al., 2011) . As far as we know, our study is the first cohort study with a prolonged follow-up period in OTRs in which the relationship between HPV serology before and just after the organ transplantation was studied in relation to later development of a first KC. Proby et al. (2011) conducted a case-control study in OTRs from The Netherlands, United Kingdom, France, and Italy to investigate the association between SCC development and seroresponses against Beta-PV combined with detection of Beta-PV DNA in plucked eyebrow hairs. A positive association was found for concordant DNA and seropositivity for HPV36 (OR 2.4; CI 1.0-5.4), with similar, but not statistically significant, associations for HPV5, HPV9, and HPV24. Concordant Beta-PV DNA presence in hair and a serological antibody response for at least one HPV type was significantly associated with SCC risk (OR 1.6; CI 1.1-2.5). Another casecontrol study conducted in immunocompetent patients in Florida, USA, revealed a positive association between seropositivity to increasing numbers of Beta-PV types and SCC (OR 1.9; 95% CI 1.2-3.0) (Iannacone et al., 2012) . A similar association for Beta-PV types DNA in eyebrow hairs was found in another clinic-based case-control study (4 types vs. HPV-negative: OR 2.0, 95% CI 1.1-3.8) (Iannacone et al., 2014) . Waterboer et al. (2008) performed a case-control study in an Italian immunocompetent population and found a significant 2-to 3-fold risk of SCC with seropositivity for any species 2 Beta-PV type (OR 3.3, 95% CI 1.2-8.7) and for the Gamma-PV types (OR 3.1, 95% CI 1.1-8.6). In a multinational case-control study in immunocompetent subjects, a positive antibody response against four or more Beta-PV types was associated with a doubled risk for SCC in Australia and the Netherlands (Bouwes Bavinck et al., 2010). Little data are published about the association between HPV infection and the development of BCC and the findings are contradictory. A relationship between seroresponses to Beta-PV and the development of BCC has been described previously (Steger et al., 1990; Stark et al., 1998; Feltkamp et al., 2003; Andersson et al., 2012) . Interestingly, Paolini et al. (2011) reported a high frequency (11.5%) of HPV15 DNA in a small cohort of BCC patients, in agreement with the observed positive association between HPV15 and BCC in our study. However, some other studies did not report a positive association between Beta-PV seroreactivity and BCC (Karagas et al., 2006; Andersson et al., 2008; Karagas et al., 2010; Iannacone et al., 2013) . A recent systematic review showed no association between Beta-PV serological responses and BCC (Bzhalava et al., 2013) . In a subgroup of patients in Florida, USA, with Beta-PV DNA-positive BCC, however, an association between a serological response against Beta-PV and BCC was observed (Iannacone et al., 2013) . In a population-based case-control study of patients with SCC, BCC, and controls from New Hampshire, USA, it was found that seropositivity to Beta-PV (OR 1.5, 95% CI 1.0-2.1) was significantly associated with SCC. This risk increased with positivity for multiple HPV types. No associations were found with BCC risk (Karagas et al., 2006) . Karagas et al. (2010) confirmed these findings in a larger group of 2366 skin cancer cases and controls. We cannot exclude, however, that the OTRs who developed BCC in our study are at increased risk of developing SCC later on, because BCCs often precede the development of SCC in these patients. HPV types tested were: 7 Alpha-HPV (HPVs 2, 3, 6, 7, 13, 16, and 27b), 16 Beta-HPV (HPVs 5, 8, 9, 15, 17, 20, 23, 24, 36, 38, 49, 75, 76, 92, 93 Besides the advantages, the retrospective design of our study also has some disadvantages. For instance, the sera we tested were not systematically collected with the purpose to study a relationship with KC but were randomly selected from routinely archived sera collected for HLA antibody screening and other diagnostic purposes. The HRs we calculated were adjusted for sex, age at transplantation, and type of transplantation (Wisgerhof et al., 2009 ). We could not adjust for other risk factors for KC, like sun exposure, sunburns, skin type, and type of immunosuppression, because these data were not systematically collected for all patients. These risk factors are associated with an increased prevalence of HPV DNA in eyebrow hairs, but it is not known whether this is also the case for Beta-PV seroresponses (Alotaibi et al., 2006; Chen et al., 2008; de Koning et al., 2009) .
A drawback of our study was that data about seroconversion were not systematically available. It can be speculated that seroconversion in the years following transplantation in OTRs who were seronegative around transplantation might have increased the risk of tumor development in the seronegative group that, if true, could have led to a stronger association between Beta-PV-type seropositivity and KC.
In general, a drawback of studies reporting the association between serological responses and skin cancer is that because of differences in the employed methodologies (initially starting with western blotting, followed by HPV-type-specific ELISAs using L1 virus-like particles, and more recently by highthroughput multiplex fluorescent bead-based assays enabling the simultaneous detection of antibody responses in large series of serologic samples against a variety of HPVs) the outcomes between the different studies cannot always be reliably compared. In our study, however, this is only true for the earlier studies referred to (western blot by Steger et al., 1990 and ELISA technique by Stark et al., 1998; Feltkamp et al., 2003) , as the other studies all used the same multiplex serology technique that was performed in the same laboratory in Heidelberg. Other factors that may explain the different associations between HPV infection and KC are differences in immunosuppressive regimens between centers that may exert different effects on the present HPV types, different exposure to sunlight reflected by the different latitudes of the centers, and differences in exposure to different HPV types.
The exact mechanism by which Beta-PV infection predisposes for the development of KC remains unclear. It has been hypothesized that the effects of the virus on UV-induced DNA damage withholds apoptosis and DNA repair by accumulation of mutations (Bouwes Bavinck and Feltkamp, 2004) . This is supported by the fact that the E6 and E7 proteins from Beta-PV types are capable of inhibiting UV-induced cell cycle checkpoints and DNA repair mechanisms Jackson and Storey, 2000; Struijk et al., 2008; Underbrink et al., 2008) . This potentially deregulates cell cycle control and growth in keratinocytes (zur Hausen, 1999; Iannacone et al., 2012) . Some Beta-PV types could upregulate the p16INK4a and Akt/P13K pathway and might have a role in the carcinogenesis of BCC (Paolini et al., 2011) . The epidemiological evidence that HPV is involved in BCC carcinogenesis, however, is much weaker compared with the possible involvement of HPV in cutaneous SCC carcinogenesis. In conclusion, a detectable seroresponse for one or more Beta-PV types around the time of transplantation predicts an increased risk for the development of KC in OTR. This study provides additional evidence that infection with Beta-PV types has a role in keratinocyte carcinogenesis. Additional studies will be necessary to confirm the observed association between Mu-PV infection and KC development.
MATERIALS AND METHODS

Study design
Between 1966 and 2006, a total of 2,136 patients were transplanted in the Leiden University Medical Center (LUMC) ( Supplementary  Figure S2 online) . OTRs consisted of both kidney transplant recipients and simultaneous pancreas-kidney transplant recipients.
During the past 25 years, sera were collected from a considerable number of OTRs. The most extensive source of sera consisted of samples collected from 1989 for clinical care-related screening and diagnostic purposes that were systematically stored in the Department of Medical Microbiology of the LUMC. In the scope of earlier casecontrol studies, additional sera had been collected and stored (Bouwes Bavinck et al., 1991; Bouwes Bavinck et al., 1993) . From the 101 patients who participated in a prospective study (Antonsson et al., 2013) , pretransplant sera were retraced from the Eurotransplant serumbank. Altogether, 7,912 sera were available from 1,269 OTRs ( Supplementary Figure S2 online) . Because of practical reasons we had to limit the number of sera to be tested to a maximum of 3,000, the number thought to provide enough statistical power to answer our questions.
We selected 648 representative sera from all 164 OTRs who developed KC during follow-up for whom at least one serum sample was available. For each of these OTRs, we selected between 3 and 5 control OTRs without skin cancer. These patients were matched for type of transplantation (kidney transplant recipients or simultaneous pancreas-kidney transplant recipients), sex, and age at transplantation, resulting in the selection of 2,112 sera from 534 OTRs without skin cancer ( Supplementary Figure S2 online) . These sera had been collected between 7 years before and 42 years after the transplantation.
As we were specifically interested in the association between seroresponses to HPV around the transplantation and the later development of KC, we further restricted our selection to OTRs who had sera collected between 1 year before and 1 year after the transplantation. This resulted in a final cohort consisting of 1,880 sera from 445 OTRs, of whom 60 had developed KC (14 only SCC, 24 only BCC, and 22 both types of skin cancer) during the 22-year follow-up period. The number of sera collected in these patients ranged from 1 to 11 (mean: 4.2, median: 4.0). The remaining sera will be analyzed in a separate study.
Data about development of KC were retracted from the LUMC oncologic database, the LUMC pathology database, and by hand searching of the medical files. The study was approved by the medical ethical committee of the LUMC. 
Serum processing and analysis
Serum samples were obtained from À 20 1C freezers at the department of Medical Microbiology. They were defrosted and pipetted in 96-well plates. Some selected serum samples were excluded from further analysis, because either they could not be found, were not properly centrifuged initially, or contained too little volume ( Supplementary Figure S7 online) . The 96-well plates were shipped on dry ice to the German Cancer Research Center (DKFZ; Heidelberg, Germany) for analysis using Luminex technology (Austin, TX). This multiplex serology technique is an antibody detection method based on glutathione S-transferase capture ELISA in combination with fluorescent bead technology. Positive serology cutoff points are standardized at 200 mean fluorescence intensity targeted on antibodies against major capsid antigen L1 of the various HPV types (Waterboer et al., 2005; Michael et al., 2008) . Sera were tested for 7 Alpha-PV (HPVs 2, 3, 6, 7, 13, 16, and 27b), 8, 9, 15, 17, 20, 23, 24, 36, 38, 49, 75, 76, 92, 93, and 96), 48, 50, 60, 65, 95, 101, and 103) , 2 Mu-PV (HPV1 and HPV63), and one Nu-PV (HPV41).
The OTRs were considered seropositive for specific HPV genera or specific HPV types if at least one of the sera tested between 1 year before and 1 year after the transplantation had a positive antibody response against these specific HPV genera or specific HPV types.
Statistical analyses
Baseline characteristics are given in percentages and simple mean calculation. Kaplan-Meier survival analyses were used in conjunction with multivariable Cox proportional hazard methods to calculate corresponding HRs with 95% CIs for development of KC in relation to HPV serology. The date of transplantation was used as opening date. As censoring dates we used the date of diagnosis of first KC, the date of the patient's death, the date of last follow-up, the date lost to follow-up, or the date of end of study (29 October 2012) . Factors considered as potential confounders were sex, type of transplantation, and age at transplantation. The Cox models were adjusted for these variables. As the variable of HPV seropositivity had a time scope of 1year before and after the transplantation (starting point), time-dependent Cox regression analyses were performed. The analyses of SCC were performed regardless of the presence of BCC among the cases and controls and the analyses of BCC were performed regardless of the presence of SCC among the cases and controls.
To investigate whether there were Beta-PV types that were the driving force causing the positive association between Beta-PV seropositivity and the development of KC, we formed three subgroups: (1) patients who were seronegative for any Beta-PV type, (2) patients who were seropositive for the specific Beta-PV type regardless of the other Beta-PV types, and (3) patients who were seronegative for the specific Beta-PV type regardless of the other Beta-PV types. The cumulative incidence of KC, SCC, and BCC was calculated with Kaplan-Meier survival analyses. In addition, we performed conditional step forward logistic regression to get a rough estimation of which individual Beta-PV may possibly contribute to the association between seropositivity and the development of KC, SCC, and/or BCC. Starting with no variables in the model, all Beta-PV types, age, sex, and type of organ were introduced into the model, starting with the most relevant one until the addition of new variables did not improve the model any longer.
All analyses were performed with SPSS 20.0 software (IBM SPSS Statistics, IBM, Chicago, IL).
